Is ResMed, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for ResMed, Inc. has moved from fair to attractive, indicating a positive shift in its perceived value. The company appears to be undervalued, with a P/E ratio of 36, which is higher than the industry average, and an EV to EBITDA ratio of 25.87. Additionally, the PEG ratio stands at 1.15, suggesting that the stock is reasonably priced relative to its growth potential.
In comparison to its peers, ResMed, Inc. has a P/E ratio of 37.73, which is higher than Edwards Lifesciences Corp.'s 31.17 but lower than Mettler-Toledo International, Inc.'s 68.83, indicating a competitive positioning within the industry. Furthermore, the company's return over the past year is 11.90%, which lags behind the S&P 500's return of 14.08%, but it has outperformed the index year-to-date with a return of 17.23% compared to 13.30%.